[1] 谢文瑞, 何兴祥. 粪菌移植与慢性肝脏疾病. 实用肝脏病杂志, 2017, 20(6):651-653. [2] Marengo A, Rosso C, Bugianesi E. Liver cancer: connections with obesity, fatty liver, and cirrhosis. Annu Rev Med, 2016, 24(67):103-17. [3] 裴颖, 黄峰, 殷宏振, 等. 去甲斑蝥酸钠对肝癌异位移植瘤小鼠肠道微生态的影响初探. 实用肝脏病杂志, 2019, 22(4):486-489. [4] 雍伟. 早期肠内免疫微生态营养对原发性肝癌患者术后临床疗效的影响. 实用肝脏病杂志, 2017, 20(3):328-332. [5] Yu LX, Schwabe RF. The gut microbiome and liver cancer: mechanisms and clinical translation. Nat Rev Gastroenterol Hepatol, 2017, 14(9):527-539. [6] Singh V, Yeoh BS, Chassaing B, et al. Dysregulated microbial fermentation of soluble fiber induces cholestatic liver cancer. Cell, 2018, 175(3):679-694. [7] Kladar NV, Gavari NS, Božin BN. Ganoderma: insights into anticancer effects. Eur J Cancer Prev, 2016, 25(5):462-471. [8] Cao Y, Xu X, Liu S, et al. Ganoderma: a cancer immunotherapy review. Front Pharmacol, 2018, 25(9):1217. [9] Ren Z, Li A, Jiang J, et al. Gut microbiome analysis as a tool towards targeted non-invasive biomarkers for early hepatocellular carcinoma. Gut, 2019, 68(6):1014-1023. [10] Tripathi A, Debelius J, Brenner DA, et al. The gut-liver axis and the intersection with the microbiome. Nat Rev Gastroenterol Hepatol, 2018, 15(7):397-411. [11] 朱露露, 任明, 马玉兰, 等. 高血压与肠道菌群的研究现状. 中华老年心脑血管病杂志, 2020, 22(2):207-209. [12] Ponziani FR, Bhoori S, Castelli C, et al. Hepatocellular carcinoma is associated with gut microbiota profile and inflammation in nonalcoholic fatty liver disease. Hepatology, 2019, 69(1):107-120. [13] Loo TM, Kamachi F, Watanabe Y, et al. Gut microbiota promotes obesity-associated liver cancer through PGE2-mediated suppression of antitumor immunity. Cancer Discov, 2017, 7(5):522-538. [14] Zheng Y, Wang T, Tu X, et al. Gut microbiome affects the response to anti-PD-1 immunotherapy in patients with hepatocellular carcinoma. J Immunother Cancer, 2019, 7(1):193. [15] Milosevic I, Vujovic A, Barac A, et al. Gut-liver axis, gut microbiota, and its modulation in the management of liver diseases: a review of the literature. Int J Mol Sci, 2019, 20(2):395. [16] Federico A, Dallio M, Caprio GG, et al. Gut microbiota and the liver. Minerva Gastroenterol Dietol, 2017, 63(4):385-398. [17] Zhang J, Liu Y, Tang Q, et al. Polysaccharide of ganoderma and its bioactivities. Adv Exp Med Biol, 2019, 2(1181):107-134. [18] Susilo RJK, Winarni D, Husen SA, et al. Hepatoprotective effect of crude polysaccharides extracted from ganoderma lucidum against carbon tetrachloride-induced liver injury in mice. Vet World, 2019, 12(12):1987-1991. [19] Zhao RL, He YM. Network pharmacology analysis of the anti-cancer pharmacological mechanisms of Ganoderma lucidum extract with experimental support using Hepa1-6-bearing C57 BL/6 mice. J Ethnopharmacol, 2018, 10(210):287-295. [20] 王婷, 周利红, 李琦, 等. 肠道菌群对肿瘤的影响及中医药调节作用研究进展. 中华中医药学刊, 2019, 37(11):2704-2707. |